Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Oncolytics Biotech Inc
T.ONC
Alternate Symbol(s):
ONCY
Healthcare
Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune...
responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:ONC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(67)
•••
Quentin30
X
View Profile
View Bullboard History
Comment by
Quentin30
on Apr 08, 2024 7:36pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Accelerated Approval, surrogate endpoints, registration
Thanks Azzak, Yes CRISPR is doing great... it's dropped from the recent high of 90 dollars per share, but that's given would be investors a chance to get on board for a lower cost basis.
...more
(5027)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 08, 2024 5:26pm
RE:RE:RE:RE:mRNA vaccine company Phase 2 trial fails on wrong biomarker
AACR 24 - BioNTech’s cancer vaccine in a phase 1 trial, patients with a difficult-to-treat type of pancreatic cancer continue to have T-cell responses. The long-term follow-up data
...more
Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
posted May 03, 2024 9:00am by
Pulsar Helium Inc.
-
|
In recognition of the recent docu-film highlighting the importance of helium in healthcare we are offering investors an opportunity to join Pulsar on the ground in Minnesota for this month's historic reservoir flow tests. CLICK HERE ...read more
(5027)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 08, 2024 5:01pm
RE:FDA offers clinical trial design on Accelerated Approval
April 08, 2024 - FDA's Richard Pazdur, M.D addressed some key topics at the FDA’s oncology department, including accelerated approval and confirmatory trial requirements, advisory
...more
(5027)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 08, 2024 1:17pm
RE:RE:AstraZeneca's ADC disappoints - on severe adverse events
Many current ADC-based treatments are associated with high discontinuation rates, especially those with the more established payload classes such as auristatins, maytansinoids and
...more
(5027)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 08, 2024 1:00pm
RE:AstraZeneca's ADC disappoints - on severe adverse events
On Friday April 05, 2024, Enhertu became the first tumor-agnostic HER2-directed therapy authorized for administration, and the first antibody-drug conjugate (ADC) to win such an indication. Data from
...more
(5027)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 08, 2024 12:49pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Accelerated Approval, surrogate endpoints, registration
It will soon enough.
(151)
•••
Buckhenry
X
View Profile
View Bullboard History
Comment by
Buckhenry
on Apr 08, 2024 12:45pm
RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Accelerated Approval, surrogate endpoints, registration
One would think after all the endless pumping by pumpers anonymous on here in the last several years this stock would be bought out or at least $20 a share. Guess the market is not paying much
...more
(11)
•••
caddisdm
X
View Profile
View Bullboard History
Comment by
caddisdm
on Apr 08, 2024 10:52am
RE:Early April, spring time thoughts…
Investor presentation has been updated to April.
(5027)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 08, 2024 10:20am
RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events
April 08, 2024 - Merck (MSD) has acquired biotech startup Abceutics in a bid to develop safer antibody-drug conjugates and minimize their off-target effects on healthy cells, according to a
...more
(5027)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 07, 2024 7:21pm
RE:RE:RE:mRNA vaccine company Phase 2 trial fails on wrong biomarker
As is happening with Candel Therapeutics, this BioNTech / Genentech collaboration is in resected pancreatic ductal adenocarcinoma (“PDAC”) not metastatic PDAC.
(1191)
•••
Azzak34
X
View Profile
View Bullboard History
Comment by
Azzak34
on Apr 07, 2024 6:50pm
RE:RE:mRNA vaccine company Phase 2 trial fails on wrong biomarker
https://investors.biontech.de/news-releases/news-release-details/three-year-phase-1-follow-data-mrna-based-individualized Have a read folks.
(846)
•••
canadafan
X
View Profile
View Bullboard History
Post by
canadafan
on Apr 07, 2024 6:32pm
Early April, spring time thoughts…
Once again , I have read through the many posts here on good old ONC bulliten board. Similar to washroom wall writing. Random name calling, put downs etc. All hiding Behind random handles etc. i try
...more
(5027)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 07, 2024 5:08pm
RE:mRNA vaccine company Phase 2 trial fails on wrong biomarker
Gritstone's disappointing result puts into doubt Granite's chances of an accelerated approval; Gritstone previously hoped to pursue this based on molecular response data, which has drawn
...more
(5027)
•••
Noteable
X
View Profile
View Bullboard History
Comment by
Noteable
on Apr 07, 2024 5:02pm
RE:RE:G12C/G12V KRAS mutation in PC & CRC patients respond to Pela
April 03, 2024 - Madeleine Armstrong - Merck (MSD) makes haste to catch up in KRAS " Merck & Co might be a latecomer to KRAS inhibition, but it clearly wants to make up for lost time.
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project
This profitable gold stock is on its way up
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company